Liminatus Pharma, Inc (NASDAQ:LIMN)
LA PALMA, CA, UNITED STATES, June 24, 2025 /EINPresswire.com/ — Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy
Since …
Liminatus Pharma, Inc (NASDAQ:LIMN)
LA PALMA, CA, UNITED STATES, June 24, 2025 /EINPresswire.com/ — Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy
Since …